Publications by authors named "Kaitlin M Yablonski"
J Immunother Cancer
March 2023
Article Synopsis
- The ENGAGE-1 study tested the monoclonal antibody GSK3174998 alone or with pembrolizumab in patients with advanced solid tumors to evaluate safety, tolerability, and clinical activity.
- Adverse events were reported in 51% of patients receiving GSK3174998 alone and 64% in those receiving it with pembrolizumab, with fatigue being the most common.
- Limited clinical activity was observed, and specific immune cell changes in the tumor microenvironment may explain some treatment responses; however, the overall efficacy did not exceed expectations based on pembrolizumab alone.
